Division Directors Conference

ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

Nature of Financial Relationships
Faculty participating in an ACR-sponsored activity must disclose to the planning committee and audience any financial or other relationship(s) with an ineligible company including, but not limited to:

1. Advisor or review panel member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/research support
6. Speaker/honoraria includes speakers bureau, symposia, and expert witness
7. Independent contractor
8. Ownership interest
9. Royalties
10. Intellectual property/patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
12. Other financial or material support

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

The planning committee and faculty reported the following disclosures.

Planning Committee
The following planning committee members have no relevant financial relationship(s) with ineligible companies to disclose.

• Charles Haberkern, MBA
• Rebecca Shepherd, MD, MBA
• Marcus Snow, MD
• Sarah Bayefsky, MD
• Adam Kilian, MD
• Bethany Marston, MD
• Benjamin Smith, PA-C
• Irene Tan, MD
• Melesia Tillman
• Saud Abaalkhail, MD
• Seth Berney, MD
• Anna Broder, MD, MSc
• Jim Oates, MD
• Debendra Pattanaik, MD
• Natasha Ruth, MD
• Sarah Baxter, MD, PhD
• Margaret Chang, MD, PhD
• Patrick Corrigan, DPT, PhD
• Ali Duarte, MD
• Ruth Fernandez Ruiz, MD, MSc
• Tate Johnson, MD
• Emily Smitherman, MD
• Louise Thoma, PhD, DPT
• Yu (Ray) Zuo, MD, MS
• Sean Fahey, MD
• Rebecca Manno, MD, MHS
• Ann Cameron Barr, MD
• Rashmi Dhital, MD
• Mohanad Elfishawi, MBBCh, MS
• Mario David Felix, MD
• Ibtissam Gad, MD
• Guy Katz, MD
• Karen Kruzer, MD
• Sara T. Patrizi, DO
• Jessica Perfetto, MD
• Didem Saygin, MD
• Austin Wheeler, MD
• Matthew Bunyard, MD
• Kevin Byrum, MD
• Sobia Hassan, RhMSUS, MRCP, MBBS
• Lisa Korn, PhD
• Aman Kugasia, MD
• Liana Fraenkel, MD, MPH

The following planning committee members have relevant financial relationship(s) with ineligible companies to disclose.

• Fotios Koumpouras, MD – AstraZeneca (Consultant/Speaker), GSK (Consultant/Speaker), Aurinia (Consultant), BMS (Consultant), Novartis (Consultant)
• Laura Sampson, PA-C – Novartis (Advisor Board), Eli Lilly (Advisory Board)
• Vaneet Sandhu, MD – GSK (Speaker), Aurinia (Speaker)
• Stacey Tarvin, MD – Pfizer (PI), UCB (PI), Roche (PI)
• Randy Cron, MD, PhD – Sobi (Consultant, CT Support), Pfizer (CT Adjudication Committee), Apollo Therapeutics (Consultant), AbbVie (CT Adjudication Committee), MedStudy (Board Review Lecturer), Lilly & Vindico Medical Education (Curbside Consultant/Speaker)
• Eyal Muscal, MD, MSc – Sobi (Consultant, Advisory Board)
• Shanthini Kasturi, MD, MS – GSK (Advisor)
• Hanna Kim, MD – Eli Lilly (Research Support)
• Maximilian Konig, MD – Argenx (Consultant), Revel (Consultant)
• Bella Mehta, MBBS, MS – Novartis (Educational Content Development)
• Naomi Patel, MD – FVC Health (Consultant), Alosa Health (Consultant)
• Kam Nola, MS, PharmD – Eli Lilly (Stock)

View ACR's ACCME disclosure practices